Advanced Search


Study ID Status Title Patient Level Data
113581 Completed A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects Study Listed on
113583 Completed An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated with or without a BRAF Inhibitor
113585 Completed Post-Authorization Safety Study (PASS) of GlaxoSmithKline Biologicals’ pandemic influenza vaccine (GSK2340272A) in the United Kingdom (UK)
113586 Completed A phase IV (not interventional), open-label, multicentre study to evaluate the reactogenicity and safety of co-administration of GlaxoSmithKline Biologicals’ DTPa (Infanrix) and IPV (Poliorix) vaccines administered as three-dose primary immunisation course at 3, 4.5 and 6 months of age in healthy children in Russian Federation
113589 Completed A randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of GSK573719 delivered once-daily over 28 days in subjects with COPD Study Listed on
113596 Completed An open label, multi-centre, non-interventional post-marketing surveillance (PMS) to monitor the safety and effectiveness of Avamys® administered in Korean patients according to the prescribing information
113598 Completed Pharmaeconomical Analysis of Total Medical Costs in Asthma and Chronic Obstructive Pulmonary Diseses (COPD) in Turkey: A Cross-sectional Study
113603 Active not recruiting An open-label Phase I drug-drug interaction study of ofatumumab with bendamustine for the treatment of subjects with indolent B-cell non-Hodgkin’s lymphoma
113615 Completed Feasibility study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 4 and 12 months of age Study Listed on
113617 Recruiting Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
113618 Active not recruiting Safety study of GSK Biologicals’ human papillomavirus vaccine (GSK-580299) in healthy female control subjects from the primary NCT00294047 study
113621 Active not recruiting Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the Primary NCT00294047 Study
113625 Completed A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects Study Listed on
113629 Completed Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 8 to 12 weeks Study Listed on
113630 Completed Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above Study Listed on
113633 Completed A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center study to Evaluate the Dose Response Relationship of GSK1278863 over the first 4 weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 over 24 weeks in Hemodialysis-Dependent Subjects with Anemia associated with Chronic Kidney Disease who Switch from Recombinant Human Erythropoietin
113634 Completed Open Label Study to Assess the Pharmacokinetics of GSK1278863A Coadministered with a High Fat Meal or an Inhibitor of CYP2C8 (gemfibrozil) Study Listed on
113635 Completed A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers
113638 Completed Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years Study Listed on
113652 Completed Evaluate (post approval) the adherence to the prescribing information for ARIXTRA® (fondaparinux) in ACS patients- commitment of the fondaparinux EU-RMP
113674 Completed Relative bioavailability study of three different tablet formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in healthy male and female volunteers (ING113674)
113676 Recruiting Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
113678 Completed An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection Study Listed on
113681 Completed Immunogenicity of the hepatitis B antigen of the GSK Biologicals’ candidate malaria vaccine (257049)
113682 Withdrawn A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Effects of SRT2104 upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.